Thrombin generation in PNH patients treated sequentially with Eculizumab and Ravulizumab: a paired analysis
{{output}}
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disorder characterized by complement-mediated hemolysis and a high thrombotic risk. The introduction of complement inhibitors has markedly reduced thromboembolic events. Eculizumab, the first approve... ...
